|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also included is the utilization of mTOR inhibitors in both advanced renal cell carcinoma (RCC) and in patients with tuberous sclerosis complex (TSC) associated angiomyolipoma (AML).
|
31080770 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors.
|
31465470 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC).
|
30158285 |
2019 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features.
|
27473523 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tivozanib (Fotivda<sup>®</sup>) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
28971328 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
29451277 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In recent years, there has been dramatic expansion of the treatment armamentarium for patients with advanced renal cell carcinoma (aRCC), including drugs targeting vascular endothelial growth factor and mammalian target of rapamycin (mTOR) pathways.
|
28383639 |
2017 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced renal cell carcinoma (RCC) remains a largely incurable disease with a grave prognosis despite the availability of a multiplicity of systemic therapies targeted against vascular endothelial growth factor, its receptors, and the mammalian target of rapamycin.
|
25811348 |
2015 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Allosteric inhibitors of the kinase mammalian target of rapamycin (mTOR) have demonstrated significant clinical activity in patients with advanced renal cell carcinoma (RCC).
|
23867512 |
2014 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mTOR pathway is an important target for anticancer drug development, and an inhibitor of this pathway has already been approved for use in humans to treat advanced renal cell carcinoma.
|
20173664 |
2010 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma.
|
17956710 |
2007 |
|
Advanced Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most established mTOR inhibitors--rapamycin and its derivatives--showed long-lasting objective tumour responses in clinical trials, with CCI-779 being a first-in-class mTOR inhibitor that improved the survival of patients with advanced renal cell carcinoma.
|
16883305 |
2006 |